RecruitingPhase 4NCT07286188

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy: A Double-Blinded Randomized Controlled Trial


Sponsor

Northwestern University

Enrollment

40 participants

Start Date

Dec 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this double blinded randomized control trial is to evaluate the impact of misoprostol on fluid deficit during hysteroscopic myomectomies. The main questions it aims to answer are: Is there is difference in fluid deficit in patients who receive misoprostol vs placebo pre operatively for hysteroscopic myomectomies? Participants will be randomized to received 800 mcg of either rectal misoprostol prior to their hysteroscopic myomectomy or 4 tablets of placebo (ZEEBO) prior to their hysteroscopic myomectomy.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether a medication called misoprostol, given rectally before a hysteroscopic myomectomy (a procedure to remove uterine fibroids through the vagina), can reduce fluid absorption during the surgery — which is a safety concern. **You may be eligible if...** - You are between 18 and 50 years old - You have uterine fibroids between 1–3 cm in size, confirmed by ultrasound or MRI in the last 12 months - You are scheduled for a hysteroscopic myomectomy using a Myosure or resectoscope device - You are willing to receive either misoprostol or a placebo rectally before the procedure - You have a negative pregnancy test before surgery **You may NOT be eligible if...** - You are pregnant or have gone through menopause - You have a history of gynecologic cancer - You have a known allergy or intolerance to misoprostol - You are outside the 18–50 age range Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMisoprostol Tabets

800 mcg of misoprostol will be administered per rectum to intervention group prior to their scheduled hysteroscopic myomectomy.

DRUGPlacebo

4 tablets of Zeebo (Microcsrystalline cellulose) placebo tablets will be placed per rectum to prior to undergoing a hysteroscopic myomectomy, for patients assigned to the placebo arm.


Locations(1)

Northwestern

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07286188